Adult acute myeloid leukemia (AML) is a highly heterogeneous stem cell malignancy characterized by the clonal expansion of immature myeloid precursors. AML may emerge de novo, following other hematopoietic malignancies or after cytotoxic therapy for other disorders. Here, we investigated the clonal vs reactive nature of residual maturing bone marrow cells in 59 newly diagnosed adult AML and mixed phenotype acute leukemia (MPAL) patients as assessed by interphase fluorescence in situ hybridization analysis of AML and myelodysplastic syndrome-associated cytogenetic alterations and/or the pattern of chromosome X inactivation, in females. In addition, we investigated the potential association between the degree of molecular/genetic involvement of hematopoiesis and coexistence of altered immunophenotypes by flow cytometry. Our results indicate that residual maturing neutrophils, monocytes and nucleated red cell precursors from the great majority of newly diagnosed AML and MPAL cases show a clonal pattern of involvement of residual maturing hematopoietic cells, in association with a greater number of altered immunophenotypes. These findings are consistent with the replacement of normal/reactive hematopoiesis by clonal myelopoiesis and/or erythropoiesis in most newly diagnosed AML and MPAL cases, supporting the notion that in most adults presenting with de novo AML, accumulation of blast cells could occur over a pre-existing clonal hematopoiesis.
INTRODUCTION
The current World Health Organization (WHO) classification of myeloid neoplasms identifies four major subgroups of heterogeneous diseases -acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and mixed myelodysplastic/myeloproliferative neoplasms-with a significant degree of overlap among them. 1 Within AML, disease heterogeneity translates into six major subgroups, each of which still contains several specific diagnostic entities. Except for a small proportion of AML cases, which carry specific recurrent cytogenetic alterations, diagnostic criteria for AML requires 420% of myeloid lineage blast cells in the bone marrow (BM), with or without previous cytotoxic therapies or MDS-associated features. 1 Among AML patients, both cases occurring de novo and secondary to cytotoxic therapies or a prior myeloid neoplasia (for example, MDS or MPN) are included, their subclassification being of utmost clinical relevance because of their distinct prognosis. [2] [3] [4] In addition, among cases classified as de novo AML, a significant percentage of patients show AML with myelodysplasia-related changes, this also represents a unique poor-prognosis WHO category of the disease, independently of the lineage and cytogenetic alterations of myeloid blast cells. 5 Overall, these criteria confirm the clinical relevance of the presence of MDS-associated features in AML, for unequivocal differential diagnosis among de novo AML, secondary AML and AML with myelodysplasia-related changes, an intermediate subgroup of AML with dysplastic BM features potentially reflecting the presence of an underlying clonal disorder of residual hematopoiesis.
At present, it is well known that neither cytomorphology nor cytogenetics alone is sensitive enough to assess the potential clonal nature of residual hematopoietic cells, in every de novo AML patient. 2, 3, 6, 7 To the best of our knowledge, no study has been reported so far in which the clonal vs reactive nature of residual mature/maturing BM cells other than blast cells, has been systematically analyzed in patients presenting with AML, as currently defined by the WHO 2008 classification. In the present study, we investigated the clonal vs reactive nature of residual maturing BM cells in newly diagnosed adult AML and mixed phenotype acute leukemia (MPAL) patients as assessed by interphase fluorescence in situ hybridization (iFISH) analysis of those chromosomal alterations that are frequently observed in AML and in MDS 1 and/or the pattern of inactivation of the X chromosome in females. 8 In addition, the potential association between the molecular findings and both dysplastic features by cytomorphology and altered immunophenotypes by multiparameter flow cytometry (FCM) was also investigated. Overall, our results indicate that residual maturing neutrophils, monocytes and nucleated red blood cells (NRBC) from the great majority of the newly diagnosed AML and MPAL cases (mostly including de novo AML) show a clonal pattern of involvement, in association with a greater number of altered immunophenotypes. These findings are consistent with the replacement of normal/reactive hematopoiesis by clonal myelopoiesis and/or erythropoiesis in most adults with newly diagnosed AML and support the notion that in the great majority of these patients, accumulation of blast cells could occur over a pre-existing clonal (dysplastic or not) hematopoiesis.
MATERIALS AND METHODS

Patients and samples
A total of 59 adult patients (23 males and 36 females; median age of 61 years) newly diagnosed with either AML (n ¼ 53) or MPAL (n ¼ 6) were included in this study. In all cases, diagnosis was established according to the WHO 2008 criteria 1 based on blood counts, clinical findings, morphological, immunophenotypical and cytogenetic/molecular data (Supplementary Table 1) .
In every case, EDTA-anticoagulated BM samples were collected at diagnosis, after informed consent was given by each individual; the study was approved by the local Ethics Committee (Institutional Review Board) of the University Hospital of Salamanca (Salamanca, Spain).
Immunophenotypic studies
Erythrocyte-lysed, freshly obtained BM samples were analyzed by a panel of four-color combinations of monoclonal antibodies (MAb) directed against cell surface membrane markers alone or cell surface membrane markers in combination with cytoplasmic (Cy) and nuclear (n) antigens, according to previously described techniques. [9] [10] [11] [12] The following pairs of fluorochrome-conjugated MAb-fluorescein isothiocyanate, phycoerythrin-were used in combination with CD45-peridinin chlorophyll protein-cyanin 5.5 (PerCPCy5.5) and CD34-allophycocyanin (APC), (1) nTdT, CyMPO; (2) CD19, CyCD79a; (3) CyCD3, CD7; (4) CD2, CD56; (5) HLA-DR, CD117; (6) HLA-DR, CD123; (7) CD11b, CD13; (8) CD15, CD16; (9) CD65, 7.1/ NG2; (10) CD36, CD64 and CD14-APC; (11) CD71, CD235a (or CD105); (12) CD38, CD203c; (13) CD61, CD25; (14) CD22, CD33 and; (15) CD300e (IREM-2), CD14. All MAb reagents were purchased from Becton/Dickinson Biosciences (BD, San Jose, CA, USA), except CD65, 7.1/NG2, CD11b, CD36, CD64, CD16, CD235a and CD203c, which were obtained from Immunotech (Marseille, France), CD38, which was purchased from Cytognos SL (Salamanca, Spain), and CD300e (IREM-2) that was obtained from Immunostep SL (Salamanca, Spain). Immediately after sample preparation, data acquisition was performed for X5 Â 10 4 cells per sample aliquot using a FACSCanto II flow cytometer (BD) equipped with the FACSDiva software program (BD). For data analysis, the INFINICYT software (Cytognos SL) was used.
Cell purification
Purification of specific BM cell populations was performed using a FACSAria flow cytometer (BD) equipped with the FACSDiva software. Before sorting, cells were stained with X4-color combinations of fluorochrome-conjugated MAb aimed at specific and simultaneous identification of the different cell populations of interest present in the sample (for example, blast cells, maturing neutrophils, monocytic cells, nucleated erythroid precursors and mature lymphocytes). The purity achieved for the FACS-sorted cell populations was systematically 497%.
iFISH studies iFISH studies aimed at detection of t(9;22), t(8;21), inv (16) , 11q23 abnormalities, -5/del(5q), -7/del(7q), del(20q), trisomy 8 and -Y, were performed on interphase nuclei from the different FACS-purified cell populations, after they were fixed in 3/1 (v/v) methanol/acetic. For this purpose, the following panel of Spectrum Orange (SO) and Spectrum Green (SO) DNA probes (Vysis Inc, Downers Grove, IL, USA) was used: LSI BCR/ABL, LSI AML1/ETO, LSI CBFB dual-color breakapart, LSI MLL dual-color breakapart, LSI EGR1/D5S23, D5S721, LSI D7S486/CEP7, LSI D20S108, CEP8 and CEPY (satellite III) probes. Hybridization with fluorochrome-labeled FISH probes was performed according to the recommendations of the manufacturer with slight modifications, as described elsewhere. 13 Fluorescence signals were evaluated as previously described 13 using a BX60 fluorescence microscope (Olympus, Hamburg, Germany) equipped with a Â 100 oil objective.
HUMARA assay
Assessment of clonality was performed on FACS-purified cell populations from female patients (n ¼ 36) using the human androgen receptor X-chromosome inactivation (HUMARA) assay. For that purpose, genomic DNA was extracted from FACS-purified blast cells, maturing neutrophils, monocytic cells, NRBC and lymphocytes using the QIAamp mini and micro DNA extraction kits (Qiagen, Valencia, CA, USA), according to the instructions of the manufacturer. Extracted DNA (20 ng) was digested overnight at 37 1C, in the presence vs absence of the HAPII (10 U/ml) methylation-sensitive restriction endonuclease (GE Healthcare, Little Chalfont, Buckinghamshire, UK) in a final volume of 50 ml. Afterward, restriction enzymes were inactivated by heating at 95 1C for 10 min. Both digested and non-digested DNA was then amplified by PCR using two sets of primers flanking the trimeric CAG repeat specific for exon 1 of the HUMARA gene: round-one primer pairs (forward: . Following the second round of amplification, PCR products were checked to confirm the amplification of the HUMARA target using 0.8% agarose gel electrophoresis stained with ethidium bromide (0.5 mg/ml). For fragment analyses, 1 ml of the PCR product was placed in 12.25 ml of Hi-DiTM formamide (Applied Biosystems) plus 0.5 mL of GENESCAN 400HD (ROX) size standard (Applied Biosystem). The mixture was sequentially denatured at 95 1C for 5 min and cooled in ice. The PCR products were examined by fragment analysis in an automated ABI PRISM 3100 genetic analyzer (Applied Biosystems). Data was analyzed using the GeneScan software (version 3.1; Applied Biosystems). Clonality was defined when the corrected ratio (CR) showed an excess of representation of one of the parental alleles over the other of X50% (CR p0.33 or X3).
8,14-16
KIT mutation studies Presence of KIT mutation was assessed in DNA samples from FACS-purified cell fractions, using a previously described PCR-clamping technique. 17, 18 Statistical methods To determine the statistical significance of differences observed between groups, the Chi-square and the Mann-Whitney U tests were used for categorical and continuous variables, respectively (SPSS software package, SPSS, Chicago, IL). P-valueso0.05 were considered to be associated with statistical significance.
RESULTS
Cytogenetic and molecular markers of blast cell clonality Overall, the clonal nature of blast cells was demonstrated in all (59/59; 100%) newly diagnosed AML and MPAL patients analyzed (Table 1) . In detail, a clonal pattern of inactivation of chromosome X was detected in 31/31 (heterozygous) females investigated, one or more chromosomal alterations were found in 32/48 (69%) cases analyzed by iFISH and the presence of KIT mutation was detected in three patients. In six female AML patients, clonality was confirmed by both the HUMARA test and iFISH, either in the absence (n ¼ 5) or in the presence of the KIT mutation (n ¼ 1). The specific chromosomal alterations detected by iFISH in leukemia blast cells included: isolated trisomy 8, 5 cases; del (5q31), 3 cases; del (7q31), 4 cases; monosomy 7, 1 case; nulisomy Y, 2 cases; del (20q12), 2 cases; t(9;22), 3 cases; t(8;21), 1 case; inv (16), 2 cases; del (7q31) in association with del (20q12), 1 case; del (7q31) plus nulisomy Y, 1 case; del (5q31) associated with trisomy 8, 2 cases; del (5q31) plus del (20q12), 1 case; del (5q31) associated with both trisomy 8 and del (7q31), 3 patients and del (5q31), del (20q12) and trisomy 8, 1 patient (Table 2 ).
Clonal involvement of residual mature/maturing BM cells Overall, the clonal nature of residual BM compartments of mature/ maturing neutrophils and monocytic cells and/or NRBC was confirmed for at least one of these three cell compartments in most newly diagnosed AML and MPAL cases (49/59; 83%) ( Figure 1 , Tables 1 and 2 ). In the majority of cases showing clonal residual mature/maturing myeloid and/or erythroid cells (clonal cases), chromosomal alterations by iFISH and/or the KIT mutation (31/49; 68%) were detected in their blast cells, while cases carrying these cytogenetic/molecular alterations represented a lower fraction (4/10, 40%; P ¼ 0.17) among newly diagnosed AML and MPAL patients in whom the presence of residual clonal maturing neutrophils, monocytes and/or NRBC could not be demonstrated (Table 2) . Of note, all the later four altered cases, were males: two showed isolated trisomy 8, one had isolated del(7q31), and one simultaneously carried del(5q31) and del(20q12) in their blast cells with apparently normal maturing myeloid and erythroid precursors (Table 2) . Conversely, all cases carrying KIT mutation, t(8;21), t(9;22) and inv(16) displayed clonal involvement of residual neutrophils, monocytes and/or NRBC. However, differences in the frequency of clonal cases in these genetic subgroups vs other AML and MPAL cases did not reach statistical significance (P40.05) due to the reduced number of the former AML cases ( Table 2) .
Frequency of cases with clonal residual hematopoiesis in distinct WHO 2008 subtypes of AML Overall, no statistically significant differences were observed as regards the distribution of cases with clonal vs non-clonal residual hematopoiesis among the different diagnostic subgroups of newly diagnosed AML (Table 3) . Despite this, it should be noted that all therapy-related AML patients (secondary AML; 3/3 cases) and CBF AML cases (5/5 cases), as well as the majority of de novo AML with myelodysplasia-related changes (AML-MRC; 24/28 cases, 86%) and MPAL (5/6 patients, 83%) patients had an underlying clonal residual hematopoiesis. Conversely, the frequency of clonal cases appeared to be slightly (P40.05) lower among de novo AML not otherwise specified (NOS; 11/15 cases, 73%) ( Table 3 and  Supplementary Table 1 ).
Immunophenotypic profile of residual BM mature/maturing granulomonocytic and NRBC The immunophenotypic profile of residual BM mature/maturing neutrophils, monocytic cells and NRBC could be analyzed in all but one AML case (58/59 cases). Overall, immunophenotypic alterations similar to those recurrently described for MDS 9, 10, [19] [20] [21] [22] were found in 52/58 cases (90%). When present, such alterations typically involved any combination of the three granulomonocytic/erythroid cell compartments analyzed. Accordingly, immunophenotypically altered neutrophils, monocytes and NRBC were found in 51/58 (88%), 38/52 (73%) and 27/45 (60%) patients, respectively (Table 4 ). The majority of cases showed altered In two cases, clonality was detected by the KIT mutation and the HUMARA test and/or iFISH.
De novo AML and MPAL and clonal residual hematopoiesis C Fernandez et al immunophenotypic profiles in two (16/58 cases; 27%) or three (29/58; 50%) cell populations, while phenotypic alterations were restricted to a single maturation-associated cell compartment in 13/58 cases (22%) ( Table 4) . Once the frequency of phenotypic alterations in distinct cell populations was compared between cases with 'clonal' vs 'non-clonal' residual hematopoiesis, the former showed a significantly higher frequency of aberrant phenotypes among maturing neutrophils (98% vs 50%; Figure 1 . Assessment of clonal residual hematopoiesis based on the HUMARA test, interphase FISH and/or the KIT mutation assays in purified blast cells as well as purified mature/maturing neutrophils, monocytic and erythroid BM cells. The HUMARA assay results in panels a and b show two different cases analyzed with the HUMARA test. An AML with (poly)clonal residual hematopoiesis is shown in panel a, where the blast cell population shows one allele to be markedly reduced in intensity after Hpall digestion compared with the level of this allele found in normal/polyclonal CD3 þ T-lymphocytes, mature/maturing granulomonocytic and erythroid precursors. An AML with clonal residual hematopoiesis is shown in panel b, where one allele is markedly reduced in intensity after Hpall digestion in each of the purified myeloid populations (for example, blast cells, neutrophils, monocytes and NRBC) analyzed vs that of CD3+ T-lymphocytes. In panel c, melting curves positive for the D816V KIT mutation in all purified BM cell populations (blast cells, neutrophils and monocytes) vs the wild-type sequence with a melting curve at 59 1C is shown. In panel d, iFISH patterns found with the D7S486/CEP7 dual-color probe, in a patient with AML and clonal residual hematopoiesis is shown. Please note that all populations from this patient, which are displayed in panel d, show the same aberrant pattern consistent with del(7q) -loss of one red signal in the presence of two green signals is interpreted as 7q-deletion-with a higher frequency of del(7q) in blast cells, neutrophils and monocytes vs erythroid nucleated precursors.
Po0.001), monocytic cells (83% vs 30%; P ¼ 0.003) and NRBC (71% vs13%; P ¼ 0.01) ( Table 4 ). In addition, for each of these three cell populations, cases with clonal residual hematopoiesis also showed a higher mean number of phenotypic alterations/case (6.9±3.0 vs 3.7±4.2, Po0.001) as well as greater number of altered cell populations/case (2.4 ± 0.8 vs 1 ± 1.2, Po0.03), than the other cases (Tables 4 and 5 ).
DISCUSSION
AML is a poor-prognosis but still highly heterogeneous disease in adults, which significantly reduces overall patient survival rates. 23, 24 For decades, it is well established that AML may emerge de novo (de novo AML) or following other hematopoietic malignancies as well as cytotoxic therapy for other disorders (secondary AML), the latter two groups being associated with a particularly unfavorable patient outcome. [2] [3] [4] 25 Because of this, the distinction between primary de novo and secondary AML represents a major goal in the classification of the disease. [26] [27] [28] [29] Differential diagnosis criteria for primary vs secondary AML have been traditionally based on the existence of another previously well-documented myeloid stem cell disorder (for example, MDS or MPN) and/or concurrence of prior administration of leukemogenic cytotoxic therapies (associated or not with specific genetic alterations). 4, [30] [31] [32] [33] [34] [35] [36] More recently, the WHO defined a new subgroup of AML cases, which have specific myelodysplasiarelated cytogenetic alterations and/or exhibit morphological dysplasia in X50% of the cells from X2 myeloid lineages.
1 Such AML with MRC cases, also show a worse prognosis vs other de novo AML cases. 5, 23, 32, [37] [38] [39] Even though, within those de novo AML patients who do not meet the criteria for AML-MRC, still a relatively significant proportion of cases show dysplastic features that are highly suspicious of an underlying clonal hematopoiesis. 40 Despite this, to the best of our knowledge, no study has been reported so far in which the clonal vs reactive nature of residual mature/maturing BM hematopoietic cells has been systematically investigated in AML.
Here, we investigated the presence of markers of clonality in residual mature/maturing hematopoietic BM cells from a series of 59 newly diagnosed adult AML and MPAL cases. Overall, our results suggest that the great majority of newly diagnosed AML cases display an underlying clonal hematopoiesis as defined by the presence of specific cytogenetic alterations and/or a clonal pattern of inactivation of chromosome X in residual BM mature/ maturing neutrophils, monocytes and/or NRBC. Interestingly, the frequency of AML cases with clonal residual hematopoiesis was invariably high among the different WHO diagnostic subtypes of the disease. Although a relatively limited number of cases were included within each specific WHO diagnostic category of AML, overall our results showed that the great majority of the de novo AML cases, including de novo AML with MRC and AML with CBFassociated recurrent genetic alterations, carry an underlying clonal hematopoiesis. Similarly, the majority of cases with AML NOS also showed blast cells coexisting with clonal residual mature/ maturing hematopoietic cells in the absence of myelodysplasiarelated changes, suggesting that by adding more AML NOS cases, significant differences will potentially be detected. Of note, the frequency of AML cases showing underlying clonal hematopoiesis within these specific subgroups of de novo AML was also similar to that of therapy-related AML and MPAL cases. De novo AML and MPAL and clonal residual hematopoiesis C Fernandez et al Altogether, these results suggest that except for a limited number of patients, most newly diagnosed adult AML and MPAL cases develop over a pre-existing clonal hematopoiesis. The demonstration that all AML and MPAL cases carrying recurrent genetic abnormalities in their blasts -for example, t(8;21), [41] [42] [43] inv (16), [44] [45] [46] BCR/ABL gene rearrangements, [47] [48] [49] KIT mutation 50 -shared these same alterations in their residual mature/maturing myeloid hematopoietic cell compartments, suggests that such alterations potentially occur in hematopoietic (myeloid) stem cells capable of multilineage differentiation at least among the cases here analyzed, in line with previous observations in some AML and MPAL, 23, 25, 32, [51] [52] [53] and also in systemic mastocytosis patients who progress to AML. 53 At the same time, these observations also indicate that such alterations would not be sufficient for transformation to acute leukemia, other genetic hits being potentially required in this process. In line with this hypothesis, previous studies have shown that most genetic alterations here investigated are also found in maturing myeloid cells from MDS and MPN patients. 18, 23, 25, 30, 32, 52, [54] [55] [56] [57] [58] [59] [60] Of note, we investigated the presence of KIT mutations in all sorted bone marrow cell compartments of three patients who were suspected of having a coexisting systemic mastocytosis; for this purpose, we used a DNA-based, low-sensitive technique that allowed us to rule out contamination by other KIT-mutated cell populations. Usage of similar approaches in future studies for the evaluation of other AML-associated mutations (for example, FLT3 and NPM1) may further contribute to increase the frequency of clonal markers in AML blasts, particularly among males with no other markers of clonality.
Despite all the above, it should be noted that the presence of an underlying clonal hematopoiesis in adults with newly diagnosed AML and MPAL, appears to be independent of the specific diagnostic subtype of the disease or the presence of myelodysplasia-related changes. However, we should be cautious in deriving such a conclusion, as the specific markers for clonality used here might have not been informative in specific cases. As an example, all female cases diagnosed with AML with MRC showed an underlying clonal hematopoiesis, whereas this was not detected in 3/14 male patients. These results may indicate that only the cytogenetic alterations present in the blast cells of the three male patients with AML with MRC might not represent a primary but a secondary cytogenetic event, restricted to the blast cell population, while the primary cytogenetic/molecular event might have gone undetected with the set of probes used. In line with this latter hypothesis, all three male AML with MRC patients who showed no clonal residual hematopoiesis on cytogenetic grounds carried multilineage morphological dysplasia, which is highly suggestive of an underlying clonal hematopoiesis.
Based on all the above, new sensitive markers for clonality directed either at the detection of primary genetic events or their consequences on the phenotypic and/or morphological appearance of the cells are needed. In this regard, multiparameter flow cytometry immunophenotyping has emerged as an attractive approach, as the presence of multiple phenotypic alterations in different compartments of BM cells have been recurrently reported in MDS. 9, 10, [19] [20] [21] [22] 40 Interestingly, our results also showed that newly diagnosed AML and MPAL patients who showed clonal hematopoiesis on molecular/cytogenetic grounds, more frequently displayed aberrant patterns of protein expression by FCM together with a greater number of aberrant phenotypes on the different populations of residual mature/maturing BM hematopoietic cells analyzed vs all other cases. However, aberrant phenotypes were also detected at lower frequencies among the latter cases. These results may suggest that in such cases, the markers used to assess clonality could be not sensitive enough (for example, assessment of clonality by the HUMARA test requires that clonally related cells represent X70% of the cells investigated 8 ); at the same time, they point out the potential utility of FCM immunophenotyping, in addition to conventional cytomorphology, for the identification of MRC in the BM of newly diagnosed AML and MPAL cases presenting as de novo cases. 9, 20 Of note, three of our AML cases -two males and one female-in whom clonal hematopoiesis could not be demonstrated by FISH and/or HUMARA, showed aberrant phenotypes in all residual hematopoietic lineages investigated (neutrophils, monocytes and NRBC); interestingly, all these three cases were classified as AML-MRC based on cytomorphology. Taken together, these results would support the notion that FCM could contribute to increase the sensitivity of conventional cytomorphology in those cases where mild or no dysplastic features are seen in residual mature/ maturing BM cells, or where they are present at relatively low frequencies among a major population of AML blasts, hampering adequate morphological assessment. Further prospective studies are required in this regard to demonstrate the combined utility of FCM and cytomorphology for the identification of AML with MRC. In summary, our results indicate that the vast majority of adults with newly diagnosed AML and MPAL displays an underlying clonal hematopoiesis, residual mature/maturing granulomonocytic and/or erythroid cells displaying chromosomal alterations, which are frequently shared by the blast cells, in addition to multiple aberrant phenotypes; noteworthy, this appears to involve most WHO 2008 diagnostic subtypes of AML and also MPAL. Whether the presence vs absence of clonal residual hematopoiesis contributes to a better prognostic stratification of newly diagnosed adult AML and MPAL patients deserves further investigations.
